How brokerages are playing Infosys, Tata Motors & Dr Reddys

Mon, Jul 15, 2013 at 09:08

| Source:
Share   .   Email   .   Print      

Dr Reddy’s

Brokerage: Citi

Rating: Buy

Target: Rs 2,125

Rationale: The approval for Dacogen is positive given the uncertainty over FDA approval timelines & the impact that it can have on street estimates for Dr Reddy's.

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.